[ET Net News Agency, 5 October 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said New Drug Application (NDA) of "PEG Sihematide injections" was accepted by the
National Medical Products Administration (NMPA).
It is a class 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co.,
Ltd., a subsidiary of the company. This drug is intended for the treatment of dialysis
patients who are receiving erythropoietin treatment due to anaemia caused by chronic
kidney disease (CKD). (RC)